A phase 1/2 study to evaluate the safety and efficacy of XNW5004, a selective EZH2 inhibitor, in subjects with relapsed/refractory non-Hodgkin lymphoma.

Authors: Lugui Qiu, Junyuan Qi, Weiwei Zheng, Zhengzi Qian, Ke-Shu Zhou, Qingqing Cai, Kaili Zhong, Hongmei Jing, Jianqiu Wu, Xiaojing Xing, Yang Cao, Xi Zhang, Dongmei Zhou, Xiaojing Yan, Zhiye Zhang, Xinquan Liang, Liping Su, Wenjuan Yu, Hongming He

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.7012

Source: Full article


Abstract

7012